


# VEGFR



## ● VEGFR inhibitors

Discovery	Cat.No.	Product Name	Information					Selectivity	Clinical Trial
2011	S1119	Cabozantinib (XL184, BMS-907351)	IC <sub>50</sub> (nM)	VEGFR2 0.035	VEGFR1 12	VEGFR3 6	Others c-Met, Ret, Kit, Flt3, Tie2, AXL	VEGFR2	Phase 2
	S1178	Regorafenib (BAY 73-4506)	IC <sub>50</sub> (nM)	VEGFR2 4.2	VEGFR1 13	VEGFR3 46	Others PDGFRβ, Kit, RET, Raf-1		Phase 2
2008	S1035	Pazopanib HCl (GW786034 HCl)	IC <sub>50</sub> (nM)	VEGFR1 10	VEGFR2 30	VEGFR3 47	Others PDGFR, FGFR, c-Kit, c-Fms		Phase 2
	S1010	Nintedanib (BIBF 1120)	IC <sub>50</sub> (nM)	VEGFR2 13	VEGFR3 13	VEGFR1 34	Others FGFR1/2/3, PDGFRα/β		Phase 2
2002	S1046	Vandetanib (ZD6474)	IC <sub>50</sub> (nM)	VEGFR2 40	VEGFR3 110		Others EGFR		Phase 1/2
	S1040	Sorafenib Tosylate	IC <sub>50</sub> (nM)	VEGFR2 90			Others Raf-1, B-Raf		Phase 2
2000	S1101	Vatalanib (PTK787) 2HCl	IC <sub>50</sub> (nM)	VEGFR2 37	VEGFR1 77	VEGFR3 660	Others Flk, c-Kit, PDGFRβ		Phase 2
	S2897	ZM 336372	IC <sub>50</sub> (μM)	VEGFR1 0.33			Others Src, Abl	VEGFR1	
2011	S2221	Apatinib	IC <sub>50</sub> (nM)	VEGFR2 1				VEGFR2	Phase 3
	S2842	SAR131675	IC <sub>50</sub> (nM)	VEGFR3 23				VEGFR3	